SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), to discuss key achievements that support the Company’s continued growth and his recent purchase of the Company’s warrants.
BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer. Speaking with SCV’s Stuart Smith, Dr. Williams first detailed his reasoning behind the purchase of his Company’s stock. Williams stated, “With my training in immunology and extensive background in the field, I have already seen technologies worth paying attention to, and I know what we have here at BriaCell is something very special.”
Dr. Williams also discussed the recent news regarding the manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison (Waisman), to manufacture Bria-Pros™, BriaCell’s off-the-shelf personalized immunotherapy for prostate cancer, and the collaboration agreement with Harvard Medical School in support of a project led by Dr. Joan S. Brugge attempting to discover new targets that may lead to the development of novel anti-cancer treatments.